AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02386111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of varlilumab and sunitinib
Description: During the treatment phase of the study, eligible patients will receive varlilumab for up to 8 cycles. Treatment cycles are 6 weeks each with varlilumab administered once every 3 weeks and sunitinib administered daily for 4 weeks followed by a 2 week rest. There is no limit on the number of cycles of sunitinib. Patients may be discontinued from receiving study treatment (sunitinib or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg or 3 mg/kg.~The Study was terminated prior to initiation of Phase II.~All patients will receive sunitinib at a dose of 50 mg.
Study NCT02951182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Study NCT01188577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Inhalation Aerosol, HFA
Description: 10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation
Study NCT01188577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine Inhalation Aerosol
Description: Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
Study NCT02951182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Study NCT02951182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-440
Study NCT02951182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Study NCT02951182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched Placebo
Study NCT01419834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humanized 3F8 Monoclonal Antibody (Hu3F8)
Description: Hu3F8 is infused IV over \~30 minutes
Study NCT02800382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Take samples
Description: Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
Study NCT02049008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
Study NCT02049008 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Photodynamic Therapy
Description: After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
Study NCT02079493 — intervention group
Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: Knee replacement
Study NCT03452722 — intervention group
Intervention type: DRUG
Intervention: intraventricual recombinant tissue plasminogen activator application
Study NCT03356470 — intervention group
Intervention type: OTHER
Intervention: F-FDG PET/CT
Description: F-FLT PET uses a thymidine analogue that accumulates in proliferating tissue. Proliferating tissue could include malignant lesions or immune cells. In this study, FLT PET/CT will be utilized as a molecular imaging tool to detect immune activation after administration of immune checkpoint blockade with pembrolizumab or nivolumab.
Study NCT01125449 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ascorbic acid (vitamin C)
Description: Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.
Study NCT00660101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine
Description: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
Study NCT03382483 — intervention group
Intervention type: DEVICE
Intervention: Low intensity pulsed ultrasound
Description: bone growth stimulator
Study NCT00661700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10mg Vardenafil for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg Vardenafil or down to 5mg Vardenafil followed by 14 weeks treatment at preferred dose.
Study NCT00661700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose
Study NCT01428193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Subjects weighing > 50 kg will receive 250 mg orally twice a day, and subjects weighing \< 50 kg will receive 125 mg orally twice a day.
Study NCT01428193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
Study NCT01428193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estrace
Description: 0.5-1 mg once a day for seven days
Study NCT03523117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Intravenous iron
Study NCT03523117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: oral iron therapy
Study NCT03751085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AW frame
Description: AW stereotactic frame for intracranial lesion biopsy
Study NCT00984581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
Study NCT00984581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
Study NCT00984581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
Study NCT02377089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trigeminal Nerve Stimulation
Description: Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the active frequency of 120 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
Study NCT02377089 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the sham frequency of 0 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
Study NCT03584269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV Device + LTOT
Description: Respiratory assistance by a facial mask without intubation or tracheotomy
Study NCT04287036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Contact Lens
Description: TEST
Study NCT04287036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® DEFINE® Radiant Sweet™
Description: CONTROL
Study NCT02880293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: melphalan (140 mg/m2 IV on day -7)
Study NCT02880293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: fludarabine (40 mg/m2/d on days -5 through -2)
Study NCT04249557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise is medicine
Description: a 12-week exercise classes program combined with other motivational skills, including feedback and information technology support. The whole program lasts for 1 year for each participant
Study NCT04423107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen, Ibuprofen
Description: Acetaminophen (Tylenol) 15 mg/kg q6h and Ibuprofen (10 mg/kg) q6h
Study NCT04423107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen, Ibuprofen, Oxycodone
Description: Acetaminophen (Tylenol) 15 mg/kg q6h, Ibuprofen q6h, and Oxycodone 0.1 mg/kg q6h
Study NCT01300312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eperisone hydrochloride and Diclofenac sodium
Description: Fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given 3 times a day after meals for 7 to 10 days
Study NCT01300312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eperisone hydrochloride
Description: eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals for 7 to 10 days
Study NCT02267174 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standardized handoff
Description: A standardized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
Study NCT02880293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: thiotepa (5 mg/kg IV on day -67)
Study NCT02880293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide (50 mg/kg IV on day +3 and +4)
Study NCT00239928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaptanib sodium
Description: 1 drop per dosed eye per protocol.
Study NCT01440088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 in Combination with Doxorubicin
Description: 300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.~Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302.
Study NCT01440088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.
Study NCT02880293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Study NCT02880293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: (15 mg/kg PO/IV TID)
Study NCT02880293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Study NCT02880293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT02031601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression
Study NCT02031601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression
Study NCT02031601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression
Study NCT02031601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
Study NCT02976961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care
Description: Information, guidance, supportive care, and psychological intervention
Study NCT04057300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Ticagrelor tablet
Study NCT04057300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Clopidogrel tablet
Study NCT04057300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid (ASA) 81mg
Description: acetylsalicylic acid tablet
Study NCT04057300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (ASA) 81mg
Description: acetylsalicylic acid tablet
Study NCT03188978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: one 40mg tablet daily for 8 weeks starting 2 weeks before the AVF creation.
Study NCT02031601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
Study NCT02031601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum (cisplatin or carboplatin)
Description: cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
Study NCT03188978 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet daily for 8 weeks starting 2 weeks before the AVF creation.
Study NCT02031601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Description: 150mg po once a day daily until disease progression
Study NCT04004520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality with Meditation
Description: The Guided Meditation Virtual Reality is a mindfulness meditation app provided on a virtual reality platform that includes a 10 minute audio meditation for relaxation along with a 3D visualization of natural settings (e.g. forest, beach, mountain).
Study NCT04004520 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Audio Control
Description: The UCLA Mindful App is an audio only mindfulness meditation for relaxation called Breath, Sound, Body Meditation that is 12 minutes in length.
Study NCT04004520 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual reality Control
Description: The Looking Glass Virtual Reality is a stereographic 3D photo viewer provided on a virtual reality platform featuring photos from around the world dating back to approximately a century ago that participants will view for 10 minutes.
Study NCT00324363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
Study NCT02031601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gefitinib
Description: 250mg po once a day daily until disease progression
Study NCT00324363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection twice daily in volumes equal to exenatide
Study NCT03684772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICVT Topical Gel
Description: Digoxin and Furosemide (0.125%)
Study NCT03684772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Topical Gel
Description: Furosemide (0.125%)
Study NCT03684772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin Topical Gel
Description: Digoxin (0.125%)
Study NCT03684772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Gel
Description: Vehicle Gel
Study NCT00279409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: double blind capsules (abilify or placebo) taken once daily, up to 10mg.
Study NCT00279409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: double blind capsules (abilify or placebo) taken once daily, up to 10mg.
Study NCT03263273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Topical Minocycline Gel
Description: Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
Study NCT03263273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Topical Minocycline Gel
Description: Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
Study NCT03263273 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical Vehicle Gel
Description: Treating Papulopustular Rosacea while monitoring for safety and efficacy of the vehicle intervention
Study NCT02134860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bed rest
Description: 8 days of full bed rest
Study NCT02134860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test with 75 g of glucose before and after bed rest
Study NCT02134860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IVGTT
Description: Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT
Study NCT02134860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive testing
Description: Daily testing of memory and concentration using standardized tests
Study NCT02134860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle and fat biopsies
Description: Biopsies will be obtained before and after bed rest
Study NCT03957759 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Structured self-monitoring during an altitude ascent and stay at high altitude
Description: Structured self-monitoring by a symptom checklist in combination with a pulse oximeter worn at the wrist in lowlanders with COPD ascending from low altitude (760m) to high altitude (3100m).
Study NCT03872661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308
Description: IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles.
Study NCT03872661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administered at a dose of 15 mg/kg on day 1 of each 21-day cycle for 4 cycles.
Study NCT03872661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed was given 500 mg/m\^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles.
Study NCT03872661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles.
Study NCT03872661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic surgery
Description: Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
Study NCT04593004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teledermatology
Description: Patients will be assessed and followed-up by trained physicians through a store-and-forward system (teledermatology online service - Evita® app), which allows patients to upload pictures of skin areas affected by acne as well as their symptoms or questions related to their disease.
Study NCT04593004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face consultation
Description: Patients will be assessed and followed-up by trained physicians through regular face-to-face outpatient consultations.
Study NCT02031601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Icotinib
Description: 125mg po three times a day daily until disease progression
Study NCT05472480 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: anthropometric and psychosocial measurements
Description: Different types of measurements will be evaluated: body mass index (BMI), weight, height, waist circumference, waist / hip ratio (WHR), waist / stature (WSR) and the ABSI a body score shape index . To complete the study, the personal experiences of the patients will be analyzed through the administration of a psycho-social questionnaire, Body Image Disturbance Questionnaire (BIDQ).
Study NCT03495765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab 0.5mcg via intravitreal injection to study eye up to monthly
Study NCT02134860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-energy X-ray Absorptiometry (DXA) scan
Description: DXA scan to evaluate fat and muscle distribution before and after bed rest